GlobalData

Diffuse large B-cell lymphoma
#Epidemiology #GlobalData #Hodgkin lymphoma #Public health

Classical Hodgkin lymphoma cases projected to reach 28,000 by 2035

The number of newly diagnosed classical Hodgkin lymphoma cases across the US, France, Germany, Italy, Spain, the UK, Japan and China (8MM) is expected to rise from 27,000 in 2025 to 28,000 by 2035, according to GlobalData. The company’s latest report, Hodgkin Lymphoma: Epidemiology Report and Forecast, projects an annual… Read More

#News

#GlobalData #Investment #Pharmaceutical industry #Politics #Tariffs #UK #United States

Is US foreign policy uncertainty strengthening confidence in the UK?

The recent UK-US policy developments are reshaping global pharmaceutical investment and launch strategies, according to intelligence platform GlobalData.  In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines and medical technologies tariff-free access to the US market for… Read More

#Business & Investment #News #Trending News

#Advanced Therapies #Cell and gene therapy #GlobalData #Investment

Investment shifting in cell and gene therapy, report reveals 

Tighter budgets and company acquisitions have altered investment in the cell and gene therapy (CGT) sector, new analysis finds.  According to a report from data and analytics company GlobalData, the CGT sector is transitioning as companies navigate a more selective and strategy-driven funding landscape.  While venture… Read More

#Business & Investment #News

International Space Station (ISS)
#Data #Drug design #Drug discovery #GlobalData

Defying gravity: Space emerges as ‘laboratory for innovation’  

Space manufacturing could become a platform for scientific discovery and biomedical advancement, according to analytics company GlobalData.  Analysis from GlobalData suggests environments in space are increasingly accessible, with pharmaceutical and biotech companies focusing on low-Earth orbit to explore new opportunities. This includes advancing drug development,… Read More

#News

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top biopharma companies report 4% market growth in Q3 2025

The top 20 global biopharmaceutical companies experienced mixed individual market capitalisation performances in Q3 2025, with those experiencing robust pipeline progress reaping success.   This resulted in a 4% quarter-on-quarter (QoQ) increase in their combined market capitalisation from $3.7 trillion on 30 June 2025 to $3.8 trillion on… Read More

#Business & Investment #News #Trends & Analysis

Obese man measures his waist
#GlobalData #GLP-1 #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Obesity drug competition expected to intensify by 2030

Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData. In February 2024, Viking Therapeutics published Phase IIa results for its VK2735 candidate, which is being investigated both as a weekly subcutaneous… Read More

#News

Johnson & Johnson head office
#Bispecific therapeutics #GlobalData #Johnson & Johnson #Myeloma #National Institute for Health and Care Excellence (NICE)

J&J will dominate bispecific T-cell engager market

Tecvayli (teclistamab) has been recommended for relapsed and refractory multiple myeloma (RRMM) in England and Wales, leading analysts to predict Johnson & Johnson (J&J) will dominate the bispecific T-cell engagers (BiTEs) market by 2030. The UK National Institute for Health and Care Excellence (NICE) recommended teclistamab… Read More

#News

Vaccine
#GlobalData #Immunology / Virology & Vaccines #TB vaccine #Tuberculosis

World Tuberculosis Day 2024: New vaccines offer hope

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. World TB Day is marked annually on 24 March, the anniversary of the discovery of the causative mycobacterium by… Read More

#News

#FDA #Finance #GlobalData #Minerva Biosciences #Neuroscience #Schizophrenia

Minerva value plummets following FDA rejection of roluperidone

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug… Read More

#News #Trending News

Stock market
#Diabetes #Eli Lilly #GlobalData #Market reporting #Novo Nordisk #Vertex #Weight loss

Lilly, Novo Nordisk and Vertex lead on market capitalisation growth

The top 20 global biopharmaceutical companies have reported 1.6% market capitalisation growth to $3.67 trillion in 2023, according to data analysts GlobalData. The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalisation shifts in 2023 amid the macroeconomic headwinds, steep patent cliffs and the… Read More

#Business & Investment #News

Market growth 2024
#Biotech #Funding #GlobalData #Investment #Market reporting

Biotech funding recovery predicted for 2024

The biotech market is heading to recovery in 2024, following a marked downturn in investment in 2022 and 2023, according to healthcare industry professionals. A GlobalData survey ‘The State of the Biopharmaceutical Industry 2024’ found that more than 40% of the healthcare industry professionals surveyed globally… Read More

#Business & Investment #News #Trending News

Vascular endothelial growth factor A
#Drug targets #Gilead Sciences #GlobalData #Krystal Biotech #Neurodegenerative disorders #Regenerative Medicine

Regenerative medicine switches to VEGF as top drug target

Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. According to analysts GlobalData, early-stage therapies are now focused on vascular endothelial growth factor (VEGF) as the top drug target, with three drugs currently in development. Surprisingly, the… Read More

#News #Trends & Analysis